A Phase 2/3 interventional study of TJ003234 and Placebo in Coronavirus Disease 2019 COVID-19, sponsored by I-Mab Biopharma US Limited. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by I-Mab Biopharma US Limited · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 539th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 70 in phase 2/3, and was the 90th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
I-Mab Biopharma US Limited is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
I-Mab Biopharma US Limited has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TJ003234
Part 1 only
Drug: TJ003234
Drug: Placebo
Part 2 Phase 3 only
Drug: TJ003234
patients receive a single infusion
patients receive a single infusion
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline
Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale. 8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.
Time frame: Day 1 through Day 30
Percentage of Recovery by Day 14
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
Time frame: Day 1 through Day 14
Percentage of Subjects Recovered on Day 30
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
Time frame: Day 1 through Day 30
All-cause Mortality Rate by Day 30
The percentage of subjects who deceased by any cause.
Time frame: Day 1 through Day 30
Time to Recovery Among Subjects Alive by Day 30
Time to sustained recovery
Time frame: Day 1 through Day 30
Length of Hospitalization
Duration of hospitalization
Time frame: Day 1 through Day 30
| Milestone | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 77 | 6 | 42 |
| Completed | 7 | 6 | 6 | 66 | 5 | 34 |
| Not completed | 1 | 2 | 2 | 11 | 1 | 8 |
Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale. 8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.
| Participants | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ0032034 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline | — | — | 56 | 5 | 27 |
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
| Participants | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| Percentage of Recovery by Day 14 | — | — | 47 | 5 | 20 |
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
| Participants | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| Percentage of Subjects Recovered on Day 30 | — | — | 56 | 5 | 27 |
The percentage of subjects who deceased by any cause.
| Participants | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003204 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| All-cause Mortality Rate by Day 30 | — | — | 7 | 1 | 9 |
Time to sustained recovery
| days | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ004309 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| Time to Recovery Among Subjects Alive by Day 30 | — | — | 8 (5 to 18) | 6.5 (4.0 to 10.0) | 10 (4 to 22) |
Duration of hospitalization
| days | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|
| Length of Hospitalization | — | — | 10 (8 to 13) | 9.5 (1 to 12) | 11 (7 to 18) |
Collected over All adverse events will be collected from the day of informed consent to Day 30.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TJ003234 3 mg/kg (Part 1) | 1/8 (12.5%) | 2/8 (25%) | 0/8 (0%) |
| TJ003234 6mg/kg (Part 1) | 1/8 (12.5%) | 4/8 (50%) | 0/8 (0%) |
| Placebo (Part 1) | 2/8 (25%) | 2/8 (25%) | 0/8 (0%) |
| TJ003234 6 mg/kg (Part 2) | 11/77 (14.3%) | 22/77 (28.6%) | 0/77 (0%) |
| TJ003234 10mg/kg (Part 2) | 1/6 (16.7%) | 1/6 (16.7%) | 0/6 (0%) |
| Placebo (Part 2) | 10/42 (23.8%) | 16/42 (38.1%) | 0/42 (0%) |
| Event | TJ003234 3 mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6 mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|---|---|
| (WORSENING) HYPOXIC RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/8 | 13/77 | 0/6 | 5/42 |
| (Worsening) PNEUMONIA (due to COVID-19)Infections and infestations | 0/8 | 0/8 | 0/8 | 3/77 | 1/6 | 1/42 |
| Cardiac ArrestCardiac disorders | 0/8 | 1/8 | 0/8 | 2/77 | 0/6 | 0/42 |
| SEPTIC SHOCKInfections and infestations | 0/8 | 1/8 | 0/8 | 6/77 | 0/6 | 4/42 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 1/8 | 0/8 | 0/8 | 2/77 | 0/6 | 3/42 |
| COVID-19Infections and infestations | 1/8 | 1/8 | 1/8 | 0/77 | 0/6 | 0/42 |
| PNEUMONIA BACTERIALInfections and infestations | 0/8 | 0/8 | 1/8 | 0/77 | 0/6 | 0/42 |
| Staphylococcal bacteraemiaInfections and infestations | 0/8 | 0/8 | 1/8 | 0/77 | 0/6 | 0/42 |
| MyopathyMusculoskeletal and connective tissue disorders | 0/8 | 1/8 | 0/8 | 0/77 | 0/6 | 0/42 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 1/8 | 0/77 | 0/6 | 0/42 |
| Age, Continuous(years) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 51.9 (36 to 80) | 58.4 (39 to 75) | 58 (19 to 80) | 55.6 (24 to 84) | 57.2 (31 to 75) | 56.4 (37 to 77) | 56 (19 to 84) |
| Sex: Female, Male(Participants) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 49 | 4 | 24 | 88 |
| Male | 4 | 5 | 4 | 28 | 2 | 18 | 61 |
| Ethnicity (NIH/OMB)(Participants) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 33 | 2 | 16 | 53 |
| Not Hispanic or Latino | 8 | 7 | 7 | 44 | 4 | 26 | 96 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 0 | 1 | 3 |
| Asian | 0 | 0 | 0 | 2 | 0 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 4 | 3 | 3 | 23 | 3 | 10 | 46 |
| White | 4 | 5 | 5 | 39 | 3 | 21 | 77 |
| More than one race | 0 | 0 | 0 | 11 | 0 | 6 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| United States | 8 | 8 | 8 | 77 | 6 | 42 | 149 |
| Height(cm) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 168.8 (144.8 to 190.5) | 166.8 (147.3 to 185.4) | 173.3 (160.0 to 190.5) | 167.1 (72.0 to 190.5) | 171.0 (160.0 to 182.9) | 168.3 (149.9 to 188.0) | 168.65 (72.0 to 190.5) |
| Weight(kg) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 101.4 (43.9 to 161.0) | 88.0 (74.0 to 138.3) | 108.9 (53.0 to 145.0) | 97.2 (43.9 to 161.0) | 98.1 (74.0 to 138.3) | 97.1 (53.0 to 145.0) | 98.3 (43.9 to 161.0) |
| Mechanical Ventilation(Participants) | TJ003234 3mg/kg (Part 1) | TJ003234 6mg/kg (Part 1) | Placebo (Part 1) | TJ003234 6mg/kg (Part 2) | TJ003234 10mg/kg (Part 2) | Placebo (Part 2) | Total |
|---|---|---|---|---|---|---|---|
| Yes | 3 | 3 | 3 | 10 | 0 | 6 | 25 |
| No | 3 | 1 | 2 | 67 | 6 | 36 | 115 |
| Unknown | 2 | 4 | 3 | 0 | 0 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Feb 2022, 21 months.
Results were first posted in May 2023, 1 year 2 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 21 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plonmarlimab
I-Mab Biopharma US Limited